Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study

IntroductionImmune-related adverse events (irAEs) induced by immune checkpoint inhibitors are difficult to predict and can lead to severe events. Although it is important to develop strategies for the early detection of severe irAEs, there is a lack of evidence on irAEs associated with ipilimumab pl...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshihiko Tasaki, Shuzo Hamamoto, Shimpei Yamashita, Junya Furukawa, Kazutoshi Fujita, Ryotaro Tomida, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yoshihisa Mimura, Yosuke Sugiyama, Rei Unno, Atsushi Okada, Takahiro Yasui, Yoko Furukawa-Hibi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
eosinophil
ipilimumab
nivolumab
immune-related adverse event
renal cell carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483956/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1483956/full

Similar Items